Involvement of serotonin 5HT1 and 5HT2 receptors and nitric oxide synthase in the medial preoptic area on gonadotropin secretion.
Due to the stimulatory action of serotonin (5HT) and nitric oxide (NO) on the secretion of gonadotropins and PRL, this work aimed at investigating the participation of serotoninergic receptors 5HT(1) and 5HT(2) of the medial preoptic area (MPOA) in the control of luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin (PRL) secretion and the possible modulation by ovarian steroids as well as the possible participation of NO as a mediator of the stimulatory effects of serotonin in the MPOA on LH secretion. Microinjections of three different doses (0.02, 0.2, and 2 ug) of methiothepin, a serotoninergic 5HT(1) antagonist or ketanserin, a seretoninergic 5HT(2) antagonist, were carried out into the MPOA in ovariectomized rats treated or not with estrogen or estrogen plus progesterone. Other groups of ovariectomized rats treated with estrogen, estrogen plus progesterone or vehicle were prepared to evaluate NOS activity in the MPOA. Plasma LH, FSH, and PRL in ovariectomized rats were not altered by the microinjection of methiothepin or ketanserin in the MPOA. Methiothepin microinjection in the MPOA reduced LH but did not change plasma FSH and PRL in ovariectomized rats treated with estrogen or estrogen plus progesterone. On the other hand, ketanserin microinjection in the MPOA reduced plasma LH and FSH but did not change plasma PRL in the animals submitted to the same steroidal treatment. NOS activity in the MPOA was significantly reduced by methiothepin or ketanserin in ovariectomized rats treated with estrogen or estrogen plus progesterone. In conclusion, this work showed that in the studied conditions, serotonin in the MPOA: (1) does not work in the control of PRL secretion through 5HT(1) and 5HT(2) receptors; (2) integrates the control of FSH secretion by 5HT(2) receptors, but not 5HT(1); (3) in the presence of estrogen, stimulates LH secretion by 5HT(1) and 5HT(2) receptors, which can be differentially modulated by progesterone; (4) at least partly, stimulates LH secretion by nitric oxide activity.
Gouveia
Elsa Maria
EM
Universidade Estadual de Maringá, Maringá, PR, Brazil.
Franci
Celso Rodrigues
CR
D000818:Animals; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006062:Gonadotropins / Q000097:blood / Q000378:metabolism*; D007276:Injections, Intraventricular; D007650:Ketanserin / Q000008:administration & dosage; D008719:Methiothepin / Q000008:administration & dosage; D008845:Microinjections; D019001:Nitric Oxide Synthase / Q000187:drug effects / Q000378:metabolism*; D010052:Ovariectomy; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044263:Receptors, Serotonin, 5-HT1 / Q000187:drug effects / Q000378:metabolism*; D044348:Receptors, Serotonin, 5-HT2 / Q000187:drug effects / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000008:administration & dosage
D004967:Estrogens; D006062:Gonadotropins; D044263:Receptors, Serotonin, 5-HT1; D044348:Receptors, Serotonin, 5-HT2; D012702:Serotonin Antagonists; D011374:Progesterone; D008719:Methiothepin; D007650:Ketanserin; D019001:Nitric Oxide Synthase